1016237-79-8

Upstream product

• 1016237-77-6 t-butyl [(2-bromo-ethyl)-(4-nitro-benzyl)-amino]acetate 
• 174137-97-4 1,4-bis(tert-butoxycarbonylmethyl)-1,4,7-triazacyclononane 
• 1016237-75-4 t-butyl [(2-hydroxy-ethyl)-(4-nitro-benzyl)-amino]acetate 
• 64834-64-6 2-(4-nitrobenzylbenzylamino)ethanol 
• 555-16-8 4-nitrobenzaldehdye 

Downstream Products

• 1016237-81-2 (4-carboxymethyl-7-{2-[carboxymethyl-(4-nitro-benzyl)-amino]-ethyl}-[1,4,7]triazonan-1-yl)-acetic acid 
• 1258946-38-1 tert-butyl 2-{[(4-aminophenyl)methyl](2-{4,7-bis[2-(tert-butoxy)-2-oxoethyl]-1,4,7-triazonan-1-yl}ethyl)amino}acetate 

Relevant academic research and scientific papers

Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using

Substituted 1,4,7-triazacyclononane-N,N′,N″-triacetic acid and 1,4,7,10-tetraazacyclcododecane-N,N′,N″,N′″-tetraacetic acid compounds with a pendant amino or hydroxyl group, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.

Novel 64Cu-radiolabeled bile acid conjugates for targeted PET imaging

A promising bifunctional chelate (N-NE3TA) was conjugated to bile acids, cholic acid (CA), deoxycholic acid (DCA), and chenodeoxycholic acid (CDCA) as tumor targeting vectors. Bile acid conjugates of N-NE3TA (CA-N-NE3TA, DCA-N-NE3TA, and CDCA-N-NE3TA) were comparatively evaluated for complexation with 64Cu, an imaging probe for positron emission tomography (PET). N-NE3TA-bile acid conjugates were evaluated for radiolabeling kinetics with 64Cu, and the corresponding 64Cu-radiolabeled conjugates were screened for complex stability in human serum and EDTA solution. The NE3TA-bile acid conjugates instantly bound to 64Cu with excellent radiolabeling efficiency at room temperature. All NE3TA-bile acid conjugates radiolabeled with 64Cu remained inert in human serum for 2 days without releasing a considerable amount of the radioactivity. The 64Cu-radiolabeled complexes were further challenged by EDTA in a 100-fold molar excess. Bile acid-N-NE3TA conjugates radiolabeled with 64Cu were quite stable with a minimal transfer of 64Cu to EDTA at 4 h time point. The in vitro data indicate that the bile acid-N-NE3TA conjugates deserve further biological evaluation for 64Cu-based targeted PET imaging applications.

Synthesis and evaluation of novel polyaminocarboxylate-based antitumor agents

Iron depletion, using iron chelators targeting transferrin receptor (TfR) and ribonucleotide reductase (RR), is proven to be effective in the treatment of cancer. We synthesized and evaluated novel polyaminocarboxylate-based chelators NETA, NE3TA, and NE3TA-Bn and their bifunctional versions C-NETA, C-NE3TA, and N-NE3TA for use in iron depletion tumor therapy. The cytotoxic activities of the novel polyaminocarboxylates were evaluated in the HeLa and HT29 colon cancer cell lines and compared to the clinically available iron depletion agent DFO and the frequently explored polyaminocarboxylate DTPA. All new chelators except C-NETA displayed enhanced cytotoxicities in both HeLa and HT29 cancer cells compared to DFO and DTPA. Incorporation of the nitro functional unit for conjugation to a targeting moiety into the two potent non-functionalized chelators NE3TA and NE3TA-Bn (C-NE3TA and N-NE3TA) was well-tolerated and resulted in a minimal decrease in cytotoxicity. Cellular uptake of C-NE3TA, examined using a confocal microscope, indicates that the chelator is taken up into HT29 cancer cells.